Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy.
Cancer Res
; 64(15): 5084-8, 2004 Aug 01.
Article
em En
| MEDLINE
| ID: mdl-15289309
ABSTRACT
Activating mutations in Ras oncoproteins represent attractive targets for cancer immunotherapy, but few vectors capable of generating immune responses required for tumor killing without vector neutralization have been described. Whole recombinant yeast heterologously expressing mammalian mutant Ras proteins were used to immunize mice in a carcinogen-induced lung tumor model. Therapeutic immunization with the whole recombinant yeast caused complete regression of established Ras mutation-bearing lung tumors in a dose-dependent, antigen-specific manner. In combination with the genomic sequencing of tumors in patients, the yeast-based immunotherapeutic approach could be applied to treat Ras mutation-bearing human cancers.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Proto-Oncogênicas p21(ras)
/
Imunoterapia
/
Neoplasias Pulmonares
/
Neoplasias Experimentais
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article